<DOC>
	<DOCNO>NCT01858480</DOCNO>
	<brief_summary>To evaluate safety determine efficacy D-ribose treatment congestive heart failure ( CHF ) subject stabilize follow hospitalization acute decompensation .</brief_summary>
	<brief_title>Study To Evaluate D-Ribose For The Treatment Congestive Heart Failure</brief_title>
	<detailed_description>This phase IIa , randomize , double-blind , placebo-controlled , multi-center study D-ribose administer via peripheral intravenous line 24 hour stabilize hospitalized patient follow standard care treatment acute decompensation CHF , follow oral dose D-ribose three time daily remainder inpatient hospital stay outpatient period 3 month . Subjects complete Pretreatment Screening procedure Investigator establish meet pre-specified criterion stabilization heart failure , randomize treatment 7 day admission hospital .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>write informed consent Health Insurance Portability Accountability Act authorization , applicable ; symptomatic heart failure ( NYHA Class II , III IV ) ≥ 30 day prior current acute decompensation episode ; ≥2 follow sign acute decompensation : jugular venous distension , rale , dyspnea , ≥ 1+ pedal edema ; admit hospital ≤ 36 hour initial evaluation ; discontinue IV inotropic support ≥ 48 hour prior Screening ; initiate Screening subject meet follow criterion stabilization : exacerbating factor address ; near optimal volume status ; transition IV oral diuretic complete ; near optimal pharmacologic therapy achieve intolerance document ; complete Screening procedure randomize treatment ≤ 7 day hospital admission ; LVEF ≤ 35 % ≤ 12 month prior Screening . female , ≥ 2 year postmenopausal , surgically sterile , practice effective contraception ; female , nonlactating , childbearing potential , negative pregnancy test result Screening ; willing abstain ribosecontaining product study . significant medical condition ( ) , Investigator 's judgment , could compromise subject 's welfare confound study result ; significant hepatic , renal , hematologic disorder/dysfunction beyond expect CHF alone ; Creatinine Clearance &lt; 30.0 mL/min Screening ; serum potassium level &lt; 3.5 milliequivalent per liter &gt; 5.7 milliequivalent per liter , serum sodium level &lt; 130 milliequivalent per liter Screening ; systolic arterial blood pressure &lt; 90 mm Hg Screening ; receive ultrafiltration current admission ; cardiac surgery ≤ 60 day prior Screening , except percutaneous intervention ; plan revascularization procedure , electrophysiologic device cardiac mechanical support implantation , cardiac transplantation , cardiac surgery ≤ 90 day study enrollment ; functional mitral valve regurgitation &gt; moderate severity ; aortic regurgitation least moderate severity ; hemodynamically significant primary cardiac valvular disease ; myocardial infarction ≤ 30 day prior Screening ; Acute Coronary Syndrome ≤ 30 day prior Screening ; know suspect righttoleft , bidirectional , transient righttoleft cardiac shunt ; sustain ventricular tachycardia ventricular fibrillation ≤ 30 day prior Screening , unless automatic implantable cardioverter defibrillator present ; atrial fibrillation within past year ; CHF relate tachyarrhythmias bradyarrhythmias ; CHF due uncorrected thyroid disease , active myocarditis , know amyloid cardiomyopathy ; angina rest slight exertion and/or unstable angina ; diagnose hypertrophic cardiomyopathy ; cerebrovascular accident ≤ 6 month prior Screening ; cardiogenic shock time initial evaluation randomization ; cardiac mechanical support ; biventricular pacer placement ≤ 60 day prior Screening need pacemaker placement current admission ; refractory , endstage heart failure ; type I type II diabetes ; history pancreatitis ; current systemic infection ; urinary tract obstruction ; morbidly obese ( weight &gt; 159 kg [ 350 lbs ] BMI &gt; 42 kg/m2 ) ; active malignancy Screening . [ Treatment basal cell stage 1 squamous cell carcinoma , cervical carcinoma situ allow ] ; terminally ill moribund condition ; history irritable bowel syndrome , inflammatory bowel disease , ischemic colitis , vascular intestinal atherosclerosis , previous bowel resection , impaction , similar gastrointestinal condition ; currently take Kayexalate® ( sodium polystyrene sulfonate ) ; allergic reaction Optison™ Definity® component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CHF</keyword>
</DOC>